Table 3.

Unadjusted and adjusted Cox regression analysis of the primary outcome in the metastatic CRPC patients receiving ADT with abiraterone versus enzalutamide

	HR (95% CI)	P value
Abiraterone (versus enzalutamide)a	1.17 (0.94-1.47)	0.154
Adjustedb	1.31 (1.05-1.63)	0.018
Age at diagnosis	1.04 (1.02-1.05)	<0.001
Afib at baseline	1.86 (1.43-2.43)	<0.001
Charlson score (CV)	1.49 (1.30-1.66)	<0.001
Charlson score (non-CV)	1.86 (1.00-1.28)	0.043

Primary outcome is composite outcomes of myocardial infarction and stroke.

CV variables include history of myocardial infarction (MI), congestive heart failure (CHF), peripheral vascular disease (PVD), cerebrovascular accident/transient ischemic attack (CVD/TIA), diabetes mellitus (DM), and hemiplegia.

Non-CV variables include age, dementia, chronic obstructive pulmonary disorder (COPD), connective tissue disease, peptic ulcer disease, liver disease, moderate-to-severe chronic kidney disease (CKD), solid tumor, leukemia, lymphoma, and acquired immunodeficiency syndrome (AIDS).

ADT, androgen deprivation therapy; Afib, atrial fibrillation; CRPC, castrate-resistant prostate cancer.

^aUnadjusted analysis.

^bAdjusting for age at dx and Charlson score [cardiovascular (CV) and non-CV].